Apixaban

Drugbox
IUPAC_name = 1-(4-methoxyphenyl)-7-oxo-6- [4-
(2-oxopiperidin-1-yl)phenyl] -4,5-
dihydropyrazolo [5,4-c] pyridine-
3-carboxamide


CAS_number = 503612-47-3
ATC_prefix =
ATC_suffix =
PubChem = 10182969
DrugBank =
C=25 | H=25 | N=5 | O=4
molecular_weight = 459.497
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = oral

Apixaban (manufacturer's designation BMS-562247-01) is a compound being investigated as an anticoagulant. It acts by inhibiting coagulation factor Xa. It is presently undergoing phase III trials in the prevention of venous thromboembolism, together with a number of related competing compounds, such as rivaroxaban. [cite journal |author=Turpie AG |title=Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases |journal=Arterioscler. Thromb. Vasc. Biol. |volume=27 |issue=6 |pages=1238–47 |year=2007 |pmid=17379841 |doi=10.1161/ATVBAHA.107.139402] It is being marketed in a joint venture by Pfizer and Bristol-Myers Squibb. [cite web |url=http://newsroom.bms.com/index.php?s=press_releases&item=254 |title=Bristol-Myers Squibb News Release 26 April 2007 |accessdate=2007-09-15 |format= |work=]

A 2007 trial showed that apixaban was equivalent to enoxaparin/open-label heparin in preventing thrombosis is patients who had undergone a knee replacement. [cite journal |author=Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D |title=The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement |journal=J. Thromb. Haemost. |volume=5 |issue=12 |pages=2368–75 |year=2007 |pmid=17868430 |doi=10.1111/j.1538-7836.2007.02764.x]

References